A third option is suppression: the United States would forgo development of ASI and stop anyone else from building it on the basis that superintelligence is just too dangerous to be unleashed on the ...

Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on ...

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...